Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rand Arafeh, Ph.D.

Title
Institution
Department
Address
Profile Picture

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Nagler A, Vredevoogd DW, Alon M, Cheng PF, Trabish S, Kalaora S, Arafeh R, Goldin V, Levesque MP, Peeper DS, Samuels Y. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma. Pigment Cell Melanoma Res. 2020 03; 33(2):334-344. PMID: 31549767.
    Citations:    
  2. Arafeh R, Flores K, Keren-Paz A, Maik-Rachline G, Gutkind N, Rosenberg S, Seger R, Samuels Y. Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells. Sci Rep. 2019 Mar 12; 9(1):4672. PMID: 30858388.
    Citations:    
  3. Alon M, Arafeh R, Lee JS, Madan S, Kalaora S, Nagler A, Abgarian T, Greenberg P, Ruppin E, Samuels Y. Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma. Oncotarget. 2019 02 12; 10(13):1344. PMID: 30863494.
    Citations:    
  4. Arafeh R, Samuels Y. PIK3CA in cancer: The past 30 years. Semin Cancer Biol. 2019 12; 59:36-49. PMID: 30742905.
    Citations:    
  5. Arafeh R, Di Pizio A, Elkahloun AG, Dym O, Niv MY, Samuels Y. RASA2 and NF1; two-negative regulators of Ras with complementary functions in melanoma. Oncogene. 2019 03; 38(13):2432-2434. PMID: 30478445.
    Citations:    
  6. Alon M, Arafeh R, Lee JS, Madan S, Kalaora S, Nagler A, Abgarian T, Greenberg P, Ruppin E, Samuels Y. CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma. Oncotarget. 2018 Jul 27; 9(58):31264-31277. PMID: 30131853.
    Citations:    
  7. Lee JS, Das A, Jerby-Arnon L, Arafeh R, Auslander N, Davidson M, McGarry L, James D, Amzallag A, Park SG, Cheng K, Robinson W, Atias D, Stossel C, Buzhor E, Stein G, Waterfall JJ, Meltzer PS, Golan T, Hannenhalli S, Gottlieb E, Benes CH, Samuels Y, Shanks E, Ruppin E. Harnessing synthetic lethality to predict the response to cancer treatment. Nat Commun. 2018 06 29; 9(1):2546. PMID: 29959327.
    Citations:    Fields:    Translation:HumansAnimalsCells
  8. Arafeh R, Flores K, Keren-Paz A, Maik-Rachline G, Gutkind N, Rosenberg S, Seger R, Samuels Y. Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells. Sci Rep. 2017 11 27; 7(1):16345. PMID: 29180761.
    Citations:    
  9. Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, Wilmott JS, Gartner JJ, Di Pizio A, Winograd-Katz S, Sindiri S, Rotkopf R, Dutton-Regester K, Johansson P, Pritchard AL, Waddell N, Hill VK, Lin JC, Hevroni Y, Rosenberg SA, Khan J, Ben-Dor S, Niv MY, Ulitsky I, Mann GJ, Scolyer RA, Hayward NK, Samuels Y. Recurrent inactivating RASA2 mutations in melanoma. Nat Genet. 2015 Dec; 47(12):1408-10. PMID: 26502337.
    Citations: 20     Fields:    Translation:Humans
  10. Salah Z, Arafeh R, Maximov V, Galasso M, Khawaled S, Abou-Sharieha S, Volinia S, Jones KB, Croce CM, Aqeilan RI. miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells. Oncotarget. 2015 Mar 10; 6(7):4920-35. PMID: 25749032.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Arafeh's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (45)
Explore
_
Co-Authors (2)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.